Blog

Post-Doctoral Fellow Dr. Lian Willetts shines light on the frontiers of discovery

Dr. Lian Willetts was awarded 2nd place in the Falling Walls Lab Finale in Berlin representing Dr. John Lewis’ lab by presenting: “Breaking the Walls of Prostate Cancer Metastasis”

Lab Falling Walls is an international competition that challenges graduate students to showcase how their research is redefining their respective fields and breaking down the walls to the next major scientific breakthrough. The University of Alberta is one of 20 approved international events, and the Sept. 30 event saw 16 outstanding examples of graduate research. Dr. Willetts was awarded 1st place during this night.

International Labs and the Finale in Berlin

Falling Walls Lab is a global scale event that takes place in different vibrant cities around the world throughout the year. The Falling Walls Lab Finale is held each year in Berlin on 8 November. The Finale gathers 100 participants, among them all winners of the international Labs.

Stay Informed

To stay up to date on all the latest news and publications, subscribe to our newsletter!

Recent Posts

goes to...APCaRI member Russ Greiner Posted on Jun 15 21 at 7:51pm
Participation Milestone! Posted on May 29 21 at 6:12pm
Raja Singh Posted on Apr 30 21 at 12:24pm

ClarityDX Prostate clinical study expanding to the United States

Oct 8, 2019: APCaRI and Nanostics Inc. are excited to announce the opening of the first recruitment site in the US for the ClarityDX Prostate clinical validation study with Century Clinical Research Inc., based in Daytona Beach, Florida. ClarityDX Prostate is a novel liquid biopsy test for the early diagnosis of clinically significant prostate cancer.

The clinical validation study targets the recruitment of 2,800 patients with elevated levels of PSA. Therefore, US recruitment will significantly accelerate the clinical study timeline and increase patient cohort diversity.

Funding support to include US patients comes from the Bird Dogs for Prostate Cancer Research, Alberta Cancer Foundation, Alberta Innovates-ASBIRI program and the University of Alberta. The US and Canadian study samples will continue to be processed in partnership with DynaLIFE Medical Labs in Edmonton, Alberta.

“We’re very happy to partner with Century Clinical Research to recruit US men to our study,” John Lewis, CEO of Nanostics said, “the Florida recruitment site will help us increase the regional diversity of our cohort and strengthen the results of our ClarityDX Prostate study, ultimately, allowing us to make the test available to men across North America.”

“Our extensive clinical trial research experience and diverse patient population in Daytona Beach makes us a perfect partner…” said Thomas Gaskin, Vice-President & CFO of Century Clinical Research, Inc., “we look forward to working with Nanostics to develop their ClarityDX Prostate test to help improve prostate cancer outcomes.”

Implementing ClarityDX Prostate may eliminate up to 600,000 unnecessary biopsies, 24,000 hospitalizations and up to 50% of unnecessary treatments for prostate cancer in North America. This equates to a projected $1.4B per year in cost savings to healthcare and a dramatic impact on the healthcare experience and quality of life for men.

About Century Clinical Research, Inc.
Century Clinical Research, Inc. has over ten years of clinical research experience in multiple specialties, including hematology and oncology. Our staff has completed numerous industry-sponsored clinical trials in phases II-IV and has an excellent track record in quality completion of critical trials. Century Clinical Research, Inc. offers a full research infrastructure and our research staff has been trained in electronic data capture with multiple sponsors. We use a computerized clinical research program for tracking study participation and regulatory documents.
Website: https://www.centuryclinical.com/century_clinical_research.html

- Unknown